ME
Medi Caps Ltd (MEDICAPQ)
₹22.94
Mkt cap
₹31 Cr
P/E ratio
—
P/B
0.26
Div yield
0.00%
ROE
−9.21%
ROCE
−9.19%
EPS (TTM)
—
Book value
₹89
52W range
20–297
Sector
Healthcare
Price history
Previous close
Incorporated in 1983, Medi-Caps Ltd is in the business of real estate and pharmaceuticals [1]
NSE MEDICAPQBSE 523144
Health check
Cautious
ProfitabilityWeak
GrowthLow
TechnicalsNeutral
52-week range
−92.27% from high₹23
₹20+12.84% from low₹297
Current
₹22.94
Prev close
₹21.98
Day
+4.37%
Price performance
1D
+4.37%
1W
0.00%
1M
−10.04%
3M
−2.63%
6M
—
1Y
—
YTD
−9.18%
Financials
Revenue, profit & margin
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 6.03 | 7.07 | 7.87 | 6.20 | 8.29 | 4.02 | 6.97 | 2.69 | 2.02 | 4.30 | 3.45 | 2.79 | 5.78 | |
| YoY Sales growth | -60.77% | -35.96% | -25.54% | -2.82% | +37.48% | -43.14% | -11.44% | -56.61% | -75.63% | +6.97% | -50.50% | +3.72% | +186.14% | |
| Expenses | 5.53 | 6.37 | 8.37 | 6.48 | 7.84 | 5.80 | 7.20 | 6.07 | 4.93 | 5.36 | 5.51 | 4.62 | 5.45 | |
| Operating Profit | 0.50 | 0.70 | -0.50 | -0.28 | 0.45 | -1.78 | -0.23 | -3.38 | -2.91 | -1.06 | -2.06 | -1.83 | 0.33 | |
| OPM % | 8.29% | 9.90% | -6.35% | -4.52% | 5.43% | -44.28% | -3.30% | -125.65% | -144.06% | -24.65% | -59.71% | -65.59% | 5.71% | |
| Other Income | 0.07 | 0.09 | 0.24 | 0.15 | 0.29 | 0.16 | 2.14 | 0.33 | 1.53 | 0.76 | 5.59 | 0.05 | 0.07 | |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Depreciation | 0.45 | 0.45 | 0.33 | 0.43 | 0.43 | 0.43 | 0.44 | 0.44 | 0.44 | 0.44 | 0.50 | 0.45 | 0.49 | |
| Profit before tax | 0.12 | 0.34 | -0.59 | -0.56 | 0.31 | -2.05 | 1.45 | -3.50 | -1.82 | -0.74 | 3.03 | -2.23 | -0.09 | |
| Tax % | 0.00% | 150.00% | 83.05% | 0.00% | 0.00% | 0.00% | -18.62% | 0.00% | 0.00% | 4.05% | -0.33% | 0.00% | 0.00% | |
| Net Profit | 0.12 | -0.16 | -1.08 | -0.56 | 0.31 | -2.05 | 1.72 | -3.49 | -1.82 | -0.77 | 3.04 | -2.23 | -0.09 | |
| EPS in Rs | 0.10 | -0.13 | -0.87 | -0.45 | 0.25 | -1.64 | 1.38 | -2.80 | -1.46 | -0.62 | 2.44 | -1.79 | -0.07 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
No reaction history yet.
No quarterly filings ingested yet.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202651.44%Promoter
Promoters51.44%
DIIs0.02%
Public48.53%
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,884.90 | 36.70 | 4,51,538 | 0.85% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹11,180.50 | 86.86 | 2,96,807 | 0.27% | 1,127 | +63.57% | 3,676 | +35.40% | 21.97% |
| Torrent Pharma. | ₹4,689.50 | 82.07 | 1,78,180 | 0.81% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,294.60 | 92.69 | 1,24,195 | 0.09% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,200.00 | 26.48 | 1,19,990 | 0.08% | 928 | −27.96% | 7,910 | +29.17% | 21.14% |
| Dr Reddy's Labs | ₹1,390.20 | 41.56 | 1,16,360 | 0.58% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,415.00 | 36.88 | 1,14,518 | 0.92% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Medi Caps | ₹23.22 | — | 31 | 0.00% | 0 | +95.05% | 6 | +186.14% | −9.19% |
| Median: 160 Co. | ₹432.20 | 32.47 | 1,987 | 0.08% | 13 | +33.73% | 179 | +21.23% | 14.94% |
Filings
Annual reports15
Announcements5
Announcement under Regulation 30 (LODR)-Newspaper Publication 6 Nov - Extract of unaudited standalone and consolidate financial results of the company for the quarter/half year ended 30.09.2026 published in free press English edition and choutha …Submission Of Unaudited Standalone & Consolidated Financial Results For The Quarter And Half Year Ended 30.09.2026 4 Nov - Board approved unaudited Q2/H1 FY2026 results on 4 Nov 2026; consolidated loss was Rs 232.12 lakh.Board Meeting Outcome for Submission Of Unaudited Standalone & Consolidated Financial Result For The Quarter And Half Year Ended 30.09.2026 4 Nov - Board approved unaudited standalone and consolidated results for quarter and half-year ended 30 September 2026.Board Meeting Intimation for (Serial No. 03/2026-27) Of The Company, Scheduled To Be Held On Wednesday, 04Th Day Of November, 2026 Pursuant To Regulation 29 Of SEBI (LODR) Regulations, 2015. 28 Oct - Board meeting on 4 Nov 2026 to approve Q2 FY27 standalone and consolidated unaudited results.Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 7 Oct - Certificate for Compliance under Reg. 74(5) of SEBI (D.P.) Regulation 2018 for the quarter ended 30.09.2026






